Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
22:37:40 EDT Sat 15 Aug 2026
Enter Symbol
or Name
USA
CA



Q:AVXL - ANAVEX LIFE SCIENCES CORPORATION - https://www.anavex.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
AVXL - Q1.02.30·3.610.13.22-0.05-1.5698.12,0784,2433.25  3.27  3.1410.40  2.25519:34:01Aug 1115 min RT 2¢

Recent Trades - Last 10 of 4243
Time ETExPriceChangeVolume
19:34:01Q3.19-0.081
19:34:01Q3.19-0.081
16:10:17Q3.23-0.042
16:10:16Q3.23-0.042
16:10:05Q3.22-0.051
16:10:04Q3.22-0.051
16:10:04Q3.22-0.051
16:04:46Q3.22-0.051
16:04:46Q3.22-0.051
16:04:32Q3.22-0.051

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-08-11 08:00U:AVXLNews ReleaseAnavex Life Sciences Highlights Highly Qualified Board and Decisive Actions to Create Long-Term Value for Stockholders
2026-08-03 08:00U:AVXLNews ReleaseAnavex Life Sciences Announces Plans to Refresh Board to Continue Overseeing Critical Progress and Stockholder Value Creation
2026-07-30 08:00U:AVXLNews ReleaseAnavex Life Sciences Reports Preliminary Second Quarter 2026 Financial Results and Provides Business Update
2026-05-22 08:00U:AVXLNews ReleaseAnavex Life Sciences Receives Expected Nasdaq Delinquency Notification
2026-05-06 07:00U:AVXLNews ReleaseAnavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer
2026-04-14 07:30U:AVXLNews ReleaseAnavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer's Disease
2026-04-07 07:30U:AVXLNews ReleaseAnavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference
2026-03-30 07:30U:AVXLNews ReleaseAnavex Life Sciences Provides Comprehensive Regulatory Update
2026-03-25 07:30U:AVXLNews ReleaseAnavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer's Disease
2026-03-23 07:30U:AVXLNews ReleaseAnavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer's Disease
2026-03-20 07:30U:AVXLNews ReleaseNew Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer's Disease
2026-03-17 07:30U:AVXLNews ReleaseAnavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson's Disease at AD/PD 2026 Conference
2026-03-03 07:30U:AVXLNews ReleaseAnavex Life Sciences to Present at the Citizens Life Sciences Conference
2026-02-25 07:30U:AVXLNews ReleaseAnavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference
2026-02-23 07:30U:AVXLNews ReleaseAnavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors
2026-02-09 07:30U:AVXLNews ReleaseAnavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update
2026-02-03 07:30U:AVXLNews ReleaseAnavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026
2026-01-13 07:30U:AVXLNews ReleaseAnavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer's Disease
2026-01-08 07:30U:AVXLNews ReleaseAnavex Life Sciences Appoints Senior Vice President Global Head of Neurology
2026-01-06 07:30U:AVXLNews ReleaseAnavex Life Sciences Receives FDA Feedback on Alzheimer's Disease Program